Federated Hermes
PLRX icon

Federated Hermes’s Pliant Therapeutics PLRX Stock Holding History

Federated Hermes’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.1K Sell
29,055
-33,596
-54% -$40.9K ﹤0.01% 1742
2026
Q1 		$78.9K Buy
62,651
+3,156
+5% +$3.98K ﹤0.01% 1615
2025
Q4 		$72.6K Buy
59,495
+4,199
+8% +$6.31K ﹤0.01% 1608
2025
Q3 		$81.8K Sell
55,296
-30,125
-35% -$46K ﹤0.01% 1605
2025
Q2 		$99.1K Buy
85,421
+26,212
+44% +$37K ﹤0.01% 1586
2025
Q1 		$79.9K Buy
59,209
+55,637
+1,558% +$338K ﹤0.01% 1597
2024
Q4 		$47K Buy
3,572
+1,363
+62% +$18.6K ﹤0.01% 1683
2024
Q3 		$24.8K Buy
+2,209
New +$27.6K ﹤0.01% 1736
2023
Q2 		– Sell
-79,732
Closed -$2.12M – 2197
2023
Q1 		$2.12M Hold
79,732
– – 0.01% 939
2022
Q4 		$1.54M Hold
79,732
– – ﹤0.01% 999
2022
Q3 		$1.67M Sell
79,732
-251,763
-76% -$4.82M ﹤0.01% 966
2022
Q2 		$2.65M Buy
331,495
+66,323
+25% +$425K 0.01% 853
2022
Q1 		$1.86M Buy
265,172
+228,554
+624% +$2.33M ﹤0.01% 1059
2021
Q4 		$494K Buy
+36,618
New +$582K ﹤0.01% 1486

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Federated Hermes's PLRX Position: Q2 2026 in Review

Federated Hermes reduced its Pliant Therapeutics (PLRX) stake by 54% in Q2 2026, selling an estimated $40.9K and leaving 29,055 shares worth $33.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1742.

Federated Hermes first reported a position in PLRX in Q4 2021 and has held it in 14 quarters since. The position peaked at $2.65M in Q2 2022. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

  • Federated Hermes held 29,055 shares of Pliant Therapeutics worth $33.1K as of Q2 2026.
  • Federated Hermes sold 33,596 Pliant Therapeutics shares in Q2 2026, an estimated $40.9K.
  • Pliant Therapeutics made up ﹤0.01% of Federated Hermes's portfolio in Q2 2026, its #1742 holding.
  • Federated Hermes first reported a position in Pliant Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Federated Hermes's Pliant Therapeutics position peaked at $2.65M in Q2 2022.
  • 86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.